10.78010.22% ( +1.000 )
Closed: Nov 6, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -23.17, below the reasonable range, cheaper than 99.92% of the time in the past 5 years, and the industry ranks 511/606, the industry Median -1.79.
-23.17xP/E
$10.78Stock price
$-0.47Earnings per share
-23.17xP/E
Stock price$10.78Earnings per share$-0.47
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.36x
- Typical range
- -5.58x–-0.52x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.60x | 162.83% | $207.00B |
MRNAUSModerna | -36.39x | 13.60% | $101.48B |
CSLLYUSCSL Limited | -25.82x | -- | $66.59B |
NTRAUSNatera | -271.87x | 10.64% | $44.78B |
RVMDUSRevolution Medicines | -22.03x | 43.93% | $41.21B |
ROIVUSRoivant Sciences | -105.48x | 146.69% | $28.08B |
INSMUSInsmed | -41.44x | 74.21% | $25.10B |
BNTXUSBioNTech SE | -12.82x | 26.88% | $21.70B |
BBIOUSBridgebio Pharma | -24.44x | 31.08% | $14.47B |
SMMTUSSummit Therapeutics | -15.64x | 19.30% | $13.03B |
KYMRUSKymera Therapeutics | -31.35x | 8.74% | $10.95B |
BMRNUSBioMarin Pharma | -567.71x | 61.50% | $10.85B |
PCVXUSVaxcyte | -8.76x | 50.42% | $10.06B |
MDGLUSMadrigal Pharma | -59.71x | 87.55% | $9.28B |
SYREUSSpyre Therapeutics | -44.03x | 56.38% | $9.86B |
IBRXUSImmunityBio | -9.22x | 151.32% | $9.15B |
ARWRUSArrowHead Pharma | -25.68x | 35,923.70% | $8.22B |
TWSTUSTwist Bioscience | -58.16x | 28.63% | $7.95B |
PRAXUSPraxis Precision Medicines | -22.86x | 3.71% | $7.75B |
RYTMUSRhythm Pharma | -39.26x | 34.73% | $7.78B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
